Xenetic Biosciences Inc Stock Price, News & Analysis

Xenetic Biosciences (NASDAQ:XBIO) has expanded its research collaboration with The Scripps Research Institute to advance its DNase platform development. The company's systemic DNase I candidate, XBIO-015, is being developed in combination with CAR-T cell therapy for both hematologic and solid tumors.

Studies have demonstrated that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and extends survival compared to CAR-T cell therapy alone. The research program will now include additional models of lymphoma and leukemia to further validate these findings.

The DNase-based platform targets neutrophil extracellular traps (NETs) in the tumor microenvironment, with preclinical data showing improved efficacy of various cancer treatments. The company is advancing towards Phase 1 clinical development for pancreatic carcinoma and other advanced solid tumors.

Xenetic Biosciences (NASDAQ:XBIO) announced that its collaboration partner PeriNess has begun patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study evaluates systemic DNase I in combination with FOLFIRINOX for first-line treatment of unresectable, locally advanced or metastatic pancreatic cancer.

The study, led by Dr. Abed Agbabrya, will assess safety, biomarker response, pharmacokinetics, and clinical activity of DNase I. Patients will receive intravenous DNase I infusions on Days 1 and 8 of 14-day cycles. The trial's effectiveness will be measured through Objective Response Rate (ORR) and Progression-Free Survival (PFS).

This initiative stems from a December 2024 Clinical Trial Services Agreement between Xenetic and PeriNess for exploring DNase as an adjunctive treatment in pancreatic carcinoma and other solid tumors.

Xenetic Biosciences (NASDAQ:XBIO) reported its Q1 2025 financial results, highlighting progress in its DNase-based technology development. The company recorded a net loss of $0.9 million with revenue increasing 16.1% to $0.6 million compared to Q1 2024. Operating expenses decreased by 13.7% to $1.5 million. The company maintains $5.2 million in cash. Key developments include a partnership with PeriNess Ltd. for clinical studies on DNase platform treating relapsed/refractory osteosarcoma and Ewing sarcoma. Xenetic is advancing towards Phase 1 clinical trials for pancreatic carcinoma treatment, with completed preliminary studies on DNase I combinations with chemotherapy, immuno-therapies, and CAR-T therapy in colorectal cancer models.

Xenetic Biosciences (NASDAQ:XBIO) has released a Virtual Investor segment featuring Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development. The segment focuses on the company's recent poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting.

The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma', highlights preclinical data in the company's immune-oncology program targeting difficult to treat cancers.

Xenetic Biosciences (NASDAQ:XBIO) has announced that its collaboration partner, PeriNess, has entered into a Clinical Study Agreement for an exploratory clinical study of XBIO-015, a systemic DNase I candidate, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma.

The study, to be conducted at Tel-Aviv Sourasky Medical Center, will primarily assess safety and tolerability of XBIO-015 in combination with relapsed chemotherapy regimens. Secondary objectives include evaluating efficacy through objective response rate and progression-free survival.

Research conducted at the center between 2013-2024 revealed that neutrophil extracellular traps (NETs) in pediatric sarcomas' tumor microenvironment is a prognostic factor, with higher NETs burden correlating to poor prognosis. XBIO-015, a recombinant DNase I enzyme, works by digesting these NETs.

This initiative follows Xenetic's December 2024 agreement with PeriNess for exploratory studies of recombinant DNase in pancreatic carcinoma and other solid tumors at Israeli medical centers.

Xenetic Biosciences (NASDAQ:XBIO) reported its financial results for FY2024, highlighting progress in its DNase-based technology development for cancer treatment. The company recorded a net loss of $4.0 million, with R&D expenses decreasing 5.9% to $3.3 million and G&A expenses declining 4.1% to $3.4 million.

Key developments include extended collaborations with the University of Virginia and Scripps Research through 2025, and a new Clinical Trial Services Agreement with PeriNess for investigator-initiated studies. The company maintained stable royalty payments of $2.5 million from its Takeda Pharmaceuticals sublicense and ended the year with $6.2 million in cash.

Xenetic's focus remains on advancing its DNase-based technology toward IND and Phase 1 clinical trials for pancreatic carcinoma and other solid tumors, with preliminary preclinical studies completed in colorectal cancer models.

Xenetic Biosciences (NASDAQ:XBIO) presented positive preclinical data at the SITC Spring Scientific 2025 Cell Therapy Meeting, demonstrating the potential of DNase I as an adjunctive treatment to enhance immunotherapeutic responses.

The study investigated co-administration of DNase I with CAR T cells in a melanoma model, showing that a single injection of DNase I (10 mg/kg) with CAR T cells effectively suppressed lung metastasis at early stages. The combination treatment led to:

• Marked suppression of tumor burden
• Decreased metastatic foci
• Prolonged survival compared to CAR T cell monotherapy
• Increased tumor-infiltrating T and CAR T cells
• Reduced T cell exhaustion markers (PD-1 and TIM-3)

The company is advancing its DNase-based technology towards Phase 1 clinical trials for pancreatic carcinoma and other solid tumors.

Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting. The event will be held from March 12-14, 2025, in San Diego, CA, with a virtual component.

The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma', will be delivered by Dr. Alexey Stepanov from The Scripps Research Institute on March 12, 2025, at 5:10 p.m. PT.

Xenetic Biosciences (NASDAQ:XBIO) announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development, participated in a Virtual Investor 'What This Means' segment. The segment focuses on discussing the company's recently announced extension of its Research Agreement with the University of Virginia for advancing its DNase-Based oncology platform, which aims to address hard-to-treat cancers.